Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2005 Nov;20(11):1038-41.
doi: 10.1111/j.1525-1497.2005.0228.x.

Buprenorphine retention in primary care

Michael D Stein  1 , Patricia Cioe, Peter D Friedmann
Affiliations

Buprenorphine retention in primary care

Michael D Stein et al. J Gen Intern Med. 2005 Nov.

Abstract

Background: This study assesses the rate and predictors of treatment retention for primary care patients with opioid dependence-prescribed buprenorphine, a long-acting partial opioid agonist.

Methods: Observational cohort study of patients prescribed buprenorphine/naloxone and followed for 6 months in the period after the adoption of buprenophine/naloxone by a primary care practice in Rhode Island. Practice policy precluded patient discharges due to continuing drug use.

Results: Patients (n=41) had a mean duration of opioid use of 15.7 years and most had a history of heroin use (63.4%). Thirty-nine percent of patients transferred from methadone maintenance. At 24 weeks, 59% remained in treatment. Nearly half of dropouts occurred in the first 30 days. Participants with opiate-positive toxicologies at week 1 were more likely to drop out of the program (P<.01) and had a significantly shorter retention time (P<.01) on average. Among other drug use and drug treatment variables, employment and addiction counseling during treatment were significantly associated with treatment retention (P=.03).

Conclusion: Retention rates in a real world, primary care-based buprenorphine maintenance practice reflect those reported in clinical trials. Abstinence during the first week of treatment and receipt of counseling were critical to patient retention.

PubMed Disclaimer

Figures

FIGURE 1
FIGURE 1
Program retention time by week 1 opiate test.
See this image and copyright information in PMC

References

    1. Hulse G, English D, Milne E, Holman C. The quantification of mortality resulting from the regular use of illicit opiates. Addiction. 1999;94:221–9. - PubMed
    1. Mark TL, Woody GE, Juday T, Kleber HD. The economic costs of heroin addiction in the United States. Drug Alc Depend. 2001;61:195–206. - PubMed
    1. Ward J, Mattick RP, Hall W. Methadone Maintenance Treatment and Other Opioid Replacement Therapies. London: Harwood Press; 1998.
    1. O'Connor PG, Fiellin DA. Pharmacologic treatment of heroin-dependent patients. Ann Int Med. 2000;133:40–54. - PubMed
    1. Fiellin DA, Barthwell AG. Center for substance abuse treatment. Guideline development for office-based pharmacotherapies for opioid dependence. J Addict Dis. 2003;22:109–20. - PubMed

Publication types